Drug Trial Radar · NCT04819568
Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock.
Last checked: Nov 20, 2026Latest source record: Nov 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
310
Planned (sponsor's estimate)
Start
Jun 25, 2021
Primary completion
Mar 19, 2022
Study completion Mar 19, 2022
Sponsor
- Lead sponsor
- Institute of Liver and Biliary Sciences, IndiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 29, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Septic shock is a major life-threatening vasodilatory shock. Vasopressor form a crucial pharmacotherapeutic option and have long been used as the first and foremost recommended therapy.(1) However, some patients may remain refractory to catecholamine, which is also known as catecholamine-resistant septic shock.(2, 3) High-dose catecholamine therapy may lead to potential side effects such as increased myocardial oxygen consumption, lethal arrthymias, and even the high risk of mortality. (4)Therefore, newer alternatives like dopamine, dobutamine, somatostatin, and terlipressin are also used. Cirrhosis is a state of hyperdynamic circulation, which worsens with the onset of infection. In septic shock, there is relative deficiency of vasopressin. (13) The mortality of septic shock in these patients still remains extremely high. Terlipressin is a synthetic vasopressin analogue with greater selectivity for the V1-receptors.(5) In cirrhotics with septic shock, terlipressin has been used either as a continuous intravenous infusion or as intravenous boluses. However, at present none of studies reveal which would be a better mode of administration in cirrhotics with septic shock considering the reversal of hemodynamics and safety of patients.
Conditions
- Liver Cirrhosis
Interventions
TerlipressinDrug
Terlipressin Bolus Max dose 2 mg/24 hr.i.e 0.5 mg qid
Standard of CareOther
Standard of Care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reversal of shockTime frame: 72 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.